Aptar Names Pharma Chief Gael Touya as Next CEO as Stephan Tanda Retires
Event summary
- Gael Touya, current President of Aptar Pharma, appointed as AptarGroup's next CEO effective September 1, 2026.
- Stephan Tanda, CEO since 2017, will retire by the end of 2026 and serve as advisor during transition.
- Touya led Aptar Pharma to 82% topline growth since 2018 through acquisitions and organic expansion.
- Under Tanda, Aptar's adjusted EBITDA margins expanded from 19% to 22% between 2017 and 2025.
The big picture
Aptar's leadership transition comes as the company seeks to balance its strong pharma segment growth with broader consumer market expansion. The shift from Tanda to Touya reflects a strategic focus on integrating pharma's science-driven approach into other business units. With 14,000 employees across 20 countries, Aptar's ability to execute this transition will be critical for maintaining its position as a global leader in drug delivery and dispensing technologies.
What we're watching
- Strategic Expansion
- How Touya will leverage his pharma expertise to drive growth in Aptar's consumer segments.
- Operational Discipline
- Whether Touya can maintain the operational discipline that characterized Tanda's tenure.
- Market Positioning
- The pace at which Aptar can solidify its leadership in regulated drug delivery and consumer dispensing.
Related topics